Scienture Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its liquid formulation of losartan, branded as ArbliTM (losartan potassium) Oral Suspension ...

Scienture shares originally traded higher on Tuesday but have since reversed and began trading lower after the company ...

Arbli is designed for patients who require or prefer an oral liquid formulation of losartan. According to Scienture, the oral suspension provides a convenient and safe option, removing the ...

The strategic financial decision comes on the heels of today's announcement that the U.S. Food and Drug Administration (FDA) has approved Scienture's New Drug Application (NDA) for Arbli ™, the first ...

HOLDINGS has completed a draw on its Equity Line of Credit to support the commercial launch of Arbli Oral Suspension, while ...

"With the FDA approval of Arbli™, we have reached a transformative milestone that positions us to address significant unmet needs for patients requiring a liquid formulation of losartan," said ...